Description of Medical ServiceAn ocular implant is surgically implanted at the pars plana. Prior to implantation, the ocular implant is filled with SusvimoŽ, a customised form of ranibizumab. Once filled and implanted, the implant is designed to be permanent and provide continuous release of ranibizumab over an extended period of time. Patients will attend a consultation to have their ocular implant refilled every six months.
Description of Medical ConditionAge related macular degeneration (AMD) is a chronic eye disease characterised by progressive degenerative abnormalities in the central retina (macula) and is the leading cause of severe vision loss and legal blindness in people over the age of 65 years. Neovascular AMD occurs in around 10-15% of overall AMD cases, and is characterised by choroidal neovascularisation, a process in which new blood vessels grow beneath the retina and macula. In neovascular AMD, the protein vascular endothelial growth factor is predominantly responsible for the abnormal growth of blood vessels and fluid leakage under the retina.
Reason for ApplicationNew MBS item
Medical Service TypeCo-dependent technology
Previous Application Number/sNot Applicable
Application FormApplication Form (PDF 1301 KB)
Application Form (Word 236 KB)
Consultation SurveyConsultation Survey (PDF 692 KB)
Consultation Survey (Word 72 KB)
MSAC consultation input must be received by no later than Friday, 11 February 2022 for it to be considered by MSAC at its March/April 2022 meeting.
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process